Country, language and currency
- Social bookmarks:
- Testimonials
-
Read more »
Our billing is certified by:
-
- Medivation Reports First Quarter Financial Results and Provides Corporate Update - MarketWatch (press release)
- Medivation Reports First Quarter Financial Results and Provides Corporate UpdateMarketWatch (press release)Continued to enroll patients in the Phase 2 TERRAIN trial, which is comparing the effect of enzalutamide versus bicalutamide, the most commonly used anti-androgen, on progression-free survival in approximately 370 men with advanced prostate cancer who
- MDVN Misses; Focus on Enzalutamide - Zacks.com
- MDVN Misses; Focus on EnzalutamideZacks
- New Therapies for Prostate Cancer: The Practicalities - OncLive
- OncLiveNew Therapies for Prostate Cancer: The PracticalitiesOncLive12,13 This investigational agent is an irreversible androgen receptor (AR) antagonist and AR signaling inhibitor, and represents an advance from the nonsteroidal AR antagonists flutamide, bicalutamide, and nilutamide
- MDVN Misses; Focus on Enzalutamide - Analyst Blog - NASDAQ
- MDVN Misses; Focus on Enzalutamide - Analyst BlogNASDAQEnzalutamide is also in a phase II study (TERRAIN), which will compare enzalutamide with bicalutamide, in advanced prostate cancer patients who have progressed following medical castration with LHRH analog therapy or surgical castration
- CEO Brennan to leave AstraZeneca as profits sink - Pharma Times
- CEO Brennan to leave AstraZeneca as profits sinkPharma TimesAs for oncology, Arimidex (anastrozole) fell 39% to $144 million, battered by patent expiries, while Casodex (bicalutamide) fell 17% to $113 million
